2025
SUSCEPTIBLE PYRAMIDAL NEURONS IN PRIMATE DORSOLATERAL PREFRONTAL CORTEX EXPRESS AN ENRICHED CALCIUM INTERACTOME: CRITICAL ROLE OF CALBINDIN AND CAV1.2 IN HIGHER-ORDER COGNITION
Datta *, Yang S, Joyce M, Woo E, McCarroll S, Gonzalez-Burgos G, Perone I, Uchendu S, Ling E, Goldman R, Berretta S, Murray J, Morozov Y, Arellano J, Duque A, Rakic P, O'dell R, van Dyck C, Lewis D, Wang M, Krienen F, Arnsten A. SUSCEPTIBLE PYRAMIDAL NEURONS IN PRIMATE DORSOLATERAL PREFRONTAL CORTEX EXPRESS AN ENRICHED CALCIUM INTERACTOME: CRITICAL ROLE OF CALBINDIN AND CAV1.2 IN HIGHER-ORDER COGNITION. The International Journal Of Neuropsychopharmacology 2025, 28: i57-i58. PMCID: PMC11814899, DOI: 10.1093/ijnp/pyae059.100.Peer-Reviewed Original ResearchDorsolateral prefrontal cortexMacaque dlPFCPrefrontal cortexWorking memoryLayer 3 pyramidal cellsAlzheimer s diseasePrefrontal cortex dysfunctionExpression of Grin2bPyramidal cellsHigher-order cognitionIncreased risk of mental disordersRisk of neuropsychiatric disordersDendritic spine pathologyRisk of mental disordersIncreased risk of neuropsychiatric disordersL-type calcium channel Cav1.2Primate dlPFCDLPFC functionCognitive deficitsLayer III pyramidal cellsMemory impairmentPsychiatric disordersBrain circuitryNeuropsychiatric disordersMental representationsPredictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease
Lanctôt K, Tumati S, Vieira D, Bawa K, Andreazza A, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Mintzer J, Herrmann N. Predictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease. Alzheimer's & Dementia 2025, 20: e095596. PMCID: PMC11712725, DOI: 10.1002/alz.095596.Peer-Reviewed Original ResearchTreatment responseBlood-based biomarkersBlood-based biomarkers of neurodegenerationNPI-aClinical predictorsAlzheimer's diseaseClinical predictors of responsePredictive value of biomarkersTumor necrosis factor-alphaOxidative stressNeurofilament lightAffecting treatment responsePredictors of responseNecrosis factor-alphaBiomarkers of neurodegenerationInterleukin (IL)-6Treatment response predictionMonths end pointAssociated with apathyValue of biomarkersNeuropsychiatric Inventory apathy subscalePresence of anxietyPeripheral inflammation
2024
Robust, fully-automated assessment of cerebral perivascular spaces and white matter lesions: a multicentre MRI longitudinal study of their evolution and association with risk of dementia and accelerated brain atrophy
Barisano G, Iv M, Choupan J, Hayden-Gephart M, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Shaw L, Liu E, Montine T, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Jiminez G, Harvey D, Donohue M, Bernstein M, Fox N, Thompson P, Schuff N, DeCarli C, Borowski B, Gunter J, Senjem M, Vemuri P, Jones D, Kantarci K, Ward C, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Landau S, Cairns N, Householder E, Reinwald L, Lee V, Korecka M, Figurski M, Crawford K, Neu S, Foroud T, Potkin S, Shen L, Kelley F, Kim S, Nho K, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Carter R, Dolen S, Schneider L, Pawluczyk S, Beccera M, Teodoro L, Spann B, Brewer J, Vanderswag H, Fleisher A, Heidebrink J, Lord J, Petersen R, Mason S, Albers C, Knopman D, Johnson K, Doody R, Meyer J, Chowdhury M, Rountree S, Dang M, Stern Y, Honig L, Bell K, Ances B, Morris J, Carroll M, Leon S, Householder E, Mintun M, Schneider S, Oliver A, Marson D, Griffith R, Clark D, Geld-macher D, Brockington J, Roberson E, Grossman H, Mitsis E, deToledo-Morrell L, Shah R, Duara R, Varon D, Greig M, Roberts P, Albert M, Onyike C, D’Agostino D, Kielb S, Galvin J, Pogorelec D, Cerbone B, Michel C, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Wong T, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Sinha P, Oates E, Conrad G, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc Adams Ortiz C, Womack K, Mathews D, Quiceno M, Arrastia R, King R, Weiner M, Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Tingus K, Woo E, Silverman D, Lu P, Bartzokis G, Radford N, Parfitt F, Kendall T, Johnson H, Farlow M, Hake A, Matthews B, Herring S, Hunt C, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Sirrel S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Allard J, Lerner A, Ogrocki P, Hudson L, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Adeli A, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Santulli R, Kitzmiller T, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Spicer K, Bachman D, Finger E, Pasternak S, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Ponto L, Shim H, Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj B. Robust, fully-automated assessment of cerebral perivascular spaces and white matter lesions: a multicentre MRI longitudinal study of their evolution and association with risk of dementia and accelerated brain atrophy. EBioMedicine 2024, 111: 105523. PMID: 39721217, PMCID: PMC11732520, DOI: 10.1016/j.ebiom.2024.105523.Peer-Reviewed Original ResearchConceptsRisk of dementiaDementia riskAccelerated brain atrophyLower risk of dementiaMeasures of cognitive functionLongitudinal studyUS National Institutes of HealthNational Institutes of HealthCombat dementiaInstitutes of HealthPerivascular spaces countAlzheimer's disease biomarkersUS National InstitutesClinical measures of cognitive functioningDementiaBrain healthMixed-effects modelsScreening toolClinical measuresConfounding factorsObservational studyCognitive declineLongitudinal trajectoriesParticipantsBrain atrophyCorrelation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J, Lanctôt K. Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2024, 37: 100012. PMID: 40086910, DOI: 10.1016/j.inpsyc.2024.100012.Peer-Reviewed Original ResearchBoston Naming TestMini-Mental State ExamCategory fluencyMild-to-moderate AD patientsClinically significant apathyCognitive change scoresModerate AD patientsHopkins Verbal LearningVerbal learningDigit spanNaming TestVerbal fluencySignificant apathyTrail MakingCognitive changesMeasure apathyMethylphenidateCognitionCognitive scoresState ExamMini-MentalChange scoresApathyAD patientsTrial 2Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J, Lanctôt K. Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Alzheimer's & Dementia 2024, 20: e091793. PMCID: PMC11710533, DOI: 10.1002/alz.091793.Peer-Reviewed Original ResearchMini-Mental State ExamBoston Naming TestDigit Span ForwardCategory fluencyWorsening apathyNPI-aCognitive testsAlzheimer's diseaseCognitive change scoresAssociated with cognitive impairmentBaseline cognitive test scoresCognitive test scoresMild to moderate ADAssociated with performanceNaming TestVerbal fluencyExecutive functionMethylphenidate treatmentMethylphenidate groupTrail MakingCognitive domainsCognitive changesMethylphenidatePlacebo-controlled trialNPI-apathyTargetTau‐1: Design of a phase 2 trial to evaluate the efficacy, safety, and tolerability of BMS‐986446, an anti‐MTBR tau monoclonal antibody, in patients with early Alzheimer’s disease
van Dyck C, Kahl A, Abelian G, Donovan M, Ahuja M, Watson D, Ossenkoppele R, Iwatsubo T, Hansson O. TargetTau‐1: Design of a phase 2 trial to evaluate the efficacy, safety, and tolerability of BMS‐986446, an anti‐MTBR tau monoclonal antibody, in patients with early Alzheimer’s disease. Alzheimer's & Dementia 2024, 20: e094677. PMCID: PMC11712654, DOI: 10.1002/alz.094677.Peer-Reviewed Original ResearchMicrotubule binding regionTau monoclonal antibodiesTau speciesTau proteinMicrotubule-associated protein tauNeurotoxic tau speciesTau-induced neurotoxicityIntracellular neurofibrillary tanglesCell surface receptorsAD clinical progressionProtein tauNeurofibrillary tanglesBinding regionMonoclonal antibodiesTau transmissionSynaptic lossExtracellular accumulationSurface receptorsTau concentrationsCerebrospinal fluid correlateAlzheimer's diseaseTauIn vitro activity studiesSelf-associationSpeciesIs there Evidence for a Continued Benefit for Long‐Term Lecanemab Treatment? A Benefit/Risk Update from Long‐Term Efficacy, Safety and Biomarker Data
van Dyck C, Sperling R, Dhadda S, Li D, Hersch S, Irizarry M, Kramer L. Is there Evidence for a Continued Benefit for Long‐Term Lecanemab Treatment? A Benefit/Risk Update from Long‐Term Efficacy, Safety and Biomarker Data. Alzheimer's & Dementia 2024, 20: e092094. PMCID: PMC11713166, DOI: 10.1002/alz.092094.Peer-Reviewed Original ResearchOpen-label extensionAlzheimer's diseaseBrain regions of individualsMultiple measures of cognitionMeasures of cognitionAmyloid-betaTau spreadingMarkers of amyloidAD studiesRegions of individualsBrain regionsHuman IgG1 monoclonal antibodyPhase 2 studyMonths of treatmentLong-term efficacyLecanemabLonger-term dosingIgG1 monoclonal antibodyInfusion reactionsMultiple measuresRandomized studyRelationships Between Retinal Amyloid Imaging and Amyloid PET in the A4 Trial
Rissman R, Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Aggarwal N, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Rafii M, Aisen P, Sperling R. Relationships Between Retinal Amyloid Imaging and Amyloid PET in the A4 Trial. Alzheimer's & Dementia 2024, 20: e090880. PMCID: PMC11716286, DOI: 10.1002/alz.090880.Peer-Reviewed Original ResearchA4 trialFeasibility of retinal imagingPositron emission tomographyAmyloid positron emission tomographyLongitudinal Evaluation of Amyloid RiskRetinal spotsCohort of individualsAnti-Amyloid TreatmentAsymptomatic Alzheimer's diseaseRetinal amyloid depositsAlzheimer's diseaseStandardized uptake value ratioAD-diagnosed patientsPilot studyRetinal imaging techniquesLongitudinal evaluationRisk detectionNon-invasive evaluationAmyloid depositsClinically normal individualsAnti-amyloidRetinal amyloid imagingParticipantsPET standardized uptake value ratioRetinal fundus imagesSelf‐reported hearing loss is associated with faster cognitive and functional decline but not diagnostic conversion in the ADNI cohort
Miller A, Sharp E, Wang S, Zhao Y, Mecca A, van Dyck C, O'Dell R, Initiative F. Self‐reported hearing loss is associated with faster cognitive and functional decline but not diagnostic conversion in the ADNI cohort. Alzheimer's & Dementia 2024, 20: 7847-7858. PMID: 39324520, PMCID: PMC11567835, DOI: 10.1002/alz.14252.Peer-Reviewed Original ResearchSelf-reported hearing lossFunctional Activities QuestionnaireHearing lossMild cognitive impairmentModifiable risk factorsMild cognitive impairment participantsFunctional declineImpairment diagnosisModified Preclinical Alzheimer Cognitive CompositeRate of functional declineRate of cognitive declinePreclinical Alzheimer Cognitive CompositeRisk factorsCognitive impairmentSignificant longitudinal associationsActivity QuestionnaireLongitudinal associationsAlzheimer's Disease Neuroimaging InitiativeLongitudinal relationshipCognitive compositeCN participantsIncreased riskCognitive declineParticipantsDiagnostic conversionValidation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET
Young J, O’Dell R, Naganawa M, Toyonaga T, Chen M, Nabulsi N, Huang Y, Cooper E, Miller A, Lam J, Bates K, Ruan A, Nelsen K, Salardini E, Carson R, van Dyck C, Mecca A. Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET. Journal Of Nuclear Medicine 2024, 65: jnumed.124.267419. PMID: 39299782, PMCID: PMC11533916, DOI: 10.2967/jnumed.124.267419.Peer-Reviewed Original ResearchDistribution volume ratioSUV ratioSynaptic densityEffect sizeAlzheimer's diseaseLongitudinal study of Alzheimer's diseaseMethods:</b> ParticipantsLongitudinal studyMeasure synaptic densityAD participantsStudy of Alzheimer's diseaseNormal cognitionReference regionOlder adultsMulticenterDensity alterationsMeasuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
Tumati S, Herrmann N, Perin J, Rosenberg P, Lerner A, Mintzer J, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Shade D, Lanctôt K. Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2. International Psychogeriatrics 2024, 36: 1232-1244. PMID: 39297292, PMCID: PMC11695175, DOI: 10.1017/s1041610224000711.Peer-Reviewed Original ResearchDementia Apathy Interview and RatingMinimal clinically important differenceDistribution-based analysisMeasure clinically relevant changesClinically important differenceClinically significant apathyAnchor-based analysesDementia careGlobal Impression of ChangeImpression of ChangeLinear mixed modelsAlzheimer's diseaseClinically relevant changesMMSE scoreImportant differenceApathy symptomsApathy ScaleControlled trialsSignificant apathyAnchor measuresDementiaStudy visitsApathy severityMethylphenidate trialSymptom severityKey Roles of CACNA1C/Cav1.2 and CALB1/Calbindin in Prefrontal Neurons Altered in Cognitive Disorders
Datta D, Yang S, Joyce M, Woo E, McCarroll S, Gonzalez-Burgos G, Perone I, Uchendu S, Ling E, Goldman M, Berretta S, Murray J, Morozov Y, Arellano J, Duque A, Rakic P, O’Dell R, van Dyck C, Lewis D, Wang M, Krienen F, Arnsten A. Key Roles of CACNA1C/Cav1.2 and CALB1/Calbindin in Prefrontal Neurons Altered in Cognitive Disorders. JAMA Psychiatry 2024, 81: 870-881. PMID: 38776078, PMCID: PMC11112502, DOI: 10.1001/jamapsychiatry.2024.1112.Peer-Reviewed Original ResearchDorsolateral prefrontal cortexPrefrontal cortexLayer III pyramidal cellsWorking memoryCognitive disordersNeuronal firingPrimate dorsolateral prefrontal cortexPyramidal cellsSpatial working memoryWorking memory performanceRisk of mental disordersCalcium-related proteinsReduced neuronal firingL-type calcium channel Cav1.2GluN2B-NMDA receptorsL-type calcium channel activityPrefrontal neuronsL-type calcium channel blockerMemory performanceL-type calcium channelsMental disordersRisk of cognitive disordersCognitive behaviorProtein expressionAssociated with increased riskCT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
Lizama B, Williams C, North H, Pandey K, Duong D, Di V, Mecca A, Blennow K, Zetterberg H, Levey A, Grundman M, van Dyck C, Caggiano A, Seyfried N, Hamby M. CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimer's & Dementia 2024, 20: 6860-6880. PMID: 39166791, PMCID: PMC11485314, DOI: 10.1002/alz.14152.Peer-Reviewed Original ResearchVolumetric magnetic resonance imagingMagnetic resonance imagingPharmacodynamic biomarkersMeta-analysisClinical developmentCerebrospinal fluidPhase 2 clinical trialResonance imagingAlzheimer's diseaseMechanism of actionClinical trialsTandem mass tag-mass spectrometryClinical cohortMild to moderate ADCandidate biomarkersCT1812CohortBiomarker signaturesBiomarkersProteomic findingsUnbiased analysisNetwork analysisAmyloid-betaSynaptic biologyBiological impactCorrection: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Honig L, Sabbagh M, van Dyck C, Sperling R, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L. Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease. Alzheimer's Research & Therapy 2024, 16: 159. PMID: 38987826, PMCID: PMC11234521, DOI: 10.1186/s13195-024-01507-7.Peer-Reviewed Original ResearchAdverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
Zeng L, Perin J, Gross A, Shade D, Lanctôt K, Lerner A, Mintzer J, Brawman‐Mintzer O, Padala P, van Dyck C, Porsteinsson A, Craft S, Levey A, Herrmann N, Rosenberg P. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). International Journal Of Geriatric Psychiatry 2024, 39: e6108. PMID: 38858522, PMCID: PMC11265565, DOI: 10.1002/gps.6108.Peer-Reviewed Original ResearchConceptsMethylphenidate groupTreating apathyPlacebo-controlled trial of methylphenidateTreatment of apathyAssociated with methylphenidateEffects of methylphenidateTrial of methylphenidateAlzheimer's diseaseFollow-upNo treatment group differencesAdverse effects of methylphenidateDiastolic blood pressureSymptom ChecklistAdverse eventsTreatment group differencesMonitoring weightMethylphenidate useMethylphenidate treatmentMedical comorbiditiesPlacebo groupParticipantsMethylphenidateGroup differencesPlacebo-controlled trialMonthly visitsUpdated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Honig L, Sabbagh M, van Dyck C, Sperling R, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L. Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease. Alzheimer's Research & Therapy 2024, 16: 105. PMID: 38730496, PMCID: PMC11084061, DOI: 10.1186/s13195-024-01441-8.Peer-Reviewed Original ResearchConceptsOpen-label extensionInfusion-related reactionsIntracerebral hemorrhageAdverse eventsAmyloid-related imaging abnormalitiesARIA-HParallel-group studyClinical laboratory parametersMonths of treatmentMild-to-moderateMagnetic resonance imagingHomozygous participantsAPOE e4 carriersDouble-blindPlacebo-controlledLaboratory parametersStudy treatmentARIA-E.Imaging abnormalitiesOptimal patient carePhysical examinationSafety resultsClinical trialsHemosiderin depositionResonance imagingThe Development of Neuroimaging Methodologies to Assist in the Diagnosis and Treatment of Alzheimer’s Disease
van Dyck C. The Development of Neuroimaging Methodologies to Assist in the Diagnosis and Treatment of Alzheimer’s Disease. Biological Psychiatry 2024, 95: s25. DOI: 10.1016/j.biopsych.2024.02.065.Peer-Reviewed Original ResearchCommentary on “Study Partner Report of Apathy in Older Adults is Associated With AD Biomarkers: Findings From the Harvard Aging Brain Study”
Khasnavis S, O'Dell R, van Dyck C, Mecca A. Commentary on “Study Partner Report of Apathy in Older Adults is Associated With AD Biomarkers: Findings From the Harvard Aging Brain Study”. American Journal Of Geriatric Psychiatry 2024, 32: 920-921. PMID: 38658231, DOI: 10.1016/j.jagp.2024.03.017.Peer-Reviewed Original ResearchAuthor Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 55. PMID: 38472206, PMCID: PMC10933370, DOI: 10.1038/s41531-024-00674-6.Peer-Reviewed Original ResearchSex differences in the pleiotropy of hearing difficulty with imaging-derived phenotypes: a brain-wide investigation
He J, Cabrera-Mendoza B, De Angelis F, Pathak G, Koller D, Curhan S, Curhan G, Mecca A, van Dyck C, Polimanti R. Sex differences in the pleiotropy of hearing difficulty with imaging-derived phenotypes: a brain-wide investigation. Brain 2024, 147: 3395-3408. PMID: 38454550, PMCID: PMC11449129, DOI: 10.1093/brain/awae077.Peer-Reviewed Original ResearchImaging-derived phenotypesHearing difficultiesBrain imaging-derived phenotypesSex-combined analysisLatent causal variable analysesMendelian randomization approachGeneralized linear regression analysisLocal genetic correlation analysisMultivariate generalized linear regression analysisGenome-wide association studiesLatent causal variableGenetic correlation analysisGenetic correlationsLocal genetic correlationMendelian randomizationPeripheral auditory systemOlder adultsGWAS dataLinear regression analysisHealth burdenGenomic regionsAssociation studiesPleiotropic regionsSex differencesTranscriptome regulation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply